OR WAIT 15 SECS
(Raleigh, NC April 6, 2009)
-Clinical Force, the first SaaS, software as a service, CTMS, announces that Gemin X Pharmaceuticals has selected Clinical Force to manage worldwide clinical trials.
As an emerging biotech company working in oncology therapeutics with operations in Montreal Canada and Malvern Pennsylvania, Gemin X Pharmaceuticals selected Clinical Force based on its cost effective monthly subscription fees, adaptable infrastructure requiring no internal IT investment or support, and flexible user interface. In addition, Gemin X expects to improve study efficiencies by requiring their CROs to use Clinical Force on outsourced studies.
“After an extensive review process we felt Clinical Force’s modular and cost effective solution met our needs. We have deployed the Project Management, Regulatory/Ethics Management, CRF Tracking, Visit Reports, and Site Payments modules as well as the Offline Client. Future phases of our project will include integration to our EDC system(s), rollout of the new Clinical Supplies module as well as other innovative functional changes to the system that will lead to process efficiencies and cost savings,” said Kevin Rechkemmer, Clinical Information Science Manager, Clinical Operations, Gemin X Pharmaceuticals.
About Clinical Force
Clinical Force delivers a fully functional Clinical Trials Management System (CTMS) to Clinical Research Organizations and Sponsors. Clinical Force is the first company to deliver the CTMS in the Software as a Service (SaaS) model enabling quick installation and a cost effective solution. Organizations in North America, South America, Africa and Europe are successfully using the CTMS to improve internal efficiencies and real time visibility of all studies from an easy to use web based solution. Clinical Force is a privately held company with strong life science pedigree, the company has offices in the US and Europe.
About Gemin X Pharmaceuticals
Gemin X is developing first-in-class cancer therapeutics based on reinitiating programmed cell death, or apoptosis, inducing cancer cell self-digestion, or autophagy, and the inhibition of metabolism in cancerous cells. Gemin X currently has several clinical development programs underway, including Phase 2 clinical trials for its lead product candidates obatoclax (GX15-070), an innovative pan Bcl-2 inhibitor, and GMX1777, a novel inhibitor of NAD+ synthesis, and preclinical studies for its Telomere Capping and SMAC Mimetic programs. Potential treatment indications for the full scope of pipeline programs span a broad range of hematological and solid tumors, including mantle cell lymphoma (MCL), melanoma, glioblastoma, small cell lung cancer (SCLC), refractory acute lymphoblastic leukemia (ALL) and mastocytosis. For more information, please visit